{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:03:54Z","timestamp":1793037834726,"version":"4.5.0"},"reference-count":5,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T00:00:00Z","timestamp":1736553600000},"content-version":"vor","delay-in-days":149,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"This article received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Acute generalised exanthematous pustulosis (AGEP) is a rare drug-induced pustular eruption characterised by the rapid onset of superficial pinhead pustules. We discuss the case of a 27-year-old man who presented with a generalised pustular eruption on the neck, trunk and limbs. He commenced upadacitinib for the treatment of atopic dermatitis (AD) 6 months before developing the rash, and the dose was increased from 15 to 30 mg daily, 3 months prior. His only other medication was oral terbinafine, for suspected tinea corporis, which was initiated 1 month before developing the pustular eruption. Laboratory investigations showed a mildly raised CRP 25 mg\/L, neutrophilia 8.22 10 \u00d7 9\/L, and a mildly raised ALT 46 U\/L. A skin biopsy showed subcorneal pustules and a few scattered keratinocytes. Upadacitinib and terbinafine were suspended and the pustular eruption resolved. Updacitinib was reintroduced 3 weeks later as the rash was thought to be due to terbinafine and the rash recurred. He was diagnosed with AGEP secondary to upadacitinib. Upadacitinib is a selective JAK inhibitor that is increasingly used for the management of AD and clinicians should be aware that AGEP is a rare but severe adverse effect.<\/jats:p>","DOI":"10.1002\/ski2.444","type":"journal-article","created":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T07:14:18Z","timestamp":1723706058000},"source":"Crossref","is-referenced-by-count":2,"title":["Acute Generalised Exanthematous Pustulosis Associated with Upadacitinib Treatment"],"prefix":"10.1093","volume":"4","author":[{"given":"Thandiwe","family":"Banda","sequence":"first","affiliation":[{"name":"Dermatology Department, Birmingham City Hospital, Sandwell and West Birmingham Hospital Trust , Birmingham ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanaa","family":"Butt","sequence":"additional","affiliation":[{"name":"Dermatology Department, Birmingham City Hospital, Sandwell and West Birmingham Hospital Trust , Birmingham ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhavi","family":"Maheshwari","sequence":"additional","affiliation":[{"name":"Histopathology Department, Royal Wolverhampton NHS Trust , Wolverhampton ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moumita","family":"Chattopadhyay","sequence":"additional","affiliation":[{"name":"Dermatology Department, Birmingham City Hospital, Sandwell and West Birmingham Hospital Trust , Birmingham ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,15]]},"reference":[{"issue":"8","key":"2025112606021943300_ski2444-bib-0001","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17081214","article-title":"Acute generalized exanthematous pustulosis: pathogenesis, genetic background, clinical variants and therapy","volume":"17","author":"Feldmeyer","year":"2016","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2025112606021943300_ski2444-bib-0002","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s40257-020-00548-6","article-title":"Selective JAK1 inhibitors for the treatment of atopic dermatitis: focus on upadacitinib and abrocitinib","volume":"21","author":"Ferreira","year":"2020","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"2025112606021943300_ski2444-bib-0003","doi-asserted-by":"publisher","DOI":"10.12890\/2019_001383","article-title":"Palmoplantar pustulosis-like eruption induced by baricitinib for treatment of rheumatoid arthritis","volume":"7","author":"Koumaki","year":"2019","journal-title":"Eur J Case Rep Intern Med"},{"issue":"6","key":"2025112606021943300_ski2444-bib-0004","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.jdcr.2019.03.024","article-title":"Palmoplantar pustulosis-like eruption following tofacitinib therapy for juvenile idiopathic arthritis","volume":"5","author":"Shibata","year":"2019","journal-title":"JAAD Case Rep"},{"issue":"7","key":"2025112606021943300_ski2444-bib-0005","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1038\/jid.2013.44","article-title":"Rare variations in IL36RN in severe adverse drug reactions manifesting as acute generalized exanthematous pustulosis","volume":"133","author":"Navarini","year":"2013","journal-title":"J Invest Dermatol"}],"container-title":["Skin Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/4\/6\/ski2.444\/61412368\/skinhd_4_6_e444.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/4\/6\/ski2.444\/61412368\/skinhd_4_6_e444.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T11:02:32Z","timestamp":1764154952000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/skinhd\/article\/doi\/10.1002\/ski2.444\/7950896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,15]]},"references-count":5,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,8,15]]},"published-print":{"date-parts":[[2024,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ski2.444","relation":{},"ISSN":["2690-442X"],"issn-type":[{"value":"2690-442X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,8,15]]},"article-number":"ski2.444"}}